Exp Clin Endocrinol Diabetes 1990; 95(1): 31-38
DOI: 10.1055/s-0029-1210931
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Survival af Islet Isografts Despite Cytotoxicity against Pancreatic Islets Measured in Vitro*)

Brigitte Ziegler, Erika Köhler, Ingrid Klöting, W. Besch, M. Ziegler
  • Central Institute of Diabetes “Gerhardt Katsch” (Director: OMR Prof. Dr. sc. med. H. Bibergeil), Karlsburg/GDR
*) Dedicated to Professor H. Bibergeil on the occasion of his 65th birthday
Further Information

Publication History



Publication Date:
16 July 2009 (online)

Summary

In this study the in vivo relevance of spleen cell anti-islet cytotoxicity measured in vitro was examined by transplantation of 1200 syngeneic islets into the spleen of rats receiving 0.5 ml complete Freund's adjuvant (CFA) 24 h before 25 mg/kg body weight streptozotocin (STZ) was given. Control rats receiving CFA or STZ alone remained normoglycaemic whereas 12 out of 21 CFA/STZ-treated rats developed a severe hyperglycaemia after three combined treatments. After the first and second combined treatment splenocytes showed a significant cytotoxicity (p < 0.01) against syngeneic islets measured by 51Cr-release. This cytotoxicity was not detectable after the third combined treatment. The CFA/STZ-induced diabetes with a residual pancreatic insulin content of only 5% was permanently reversed by intrasplenic islet isografts, but, surprisingly, syngeneic islets survived too, if transplanted at the time when an anti-islet cytotoxicity was measured in vitro.

From our results we conclude that the polyclonal activation by complete Freund's adjuvant potentiates the beta cell-toxic effect of a low dose of streptozotocin and induced a transient splenocyte-mediated anti-islet cytotoxicity not recurrent after islet transplantation. Furthermore, our findings reveal a discrepancy between organ-specific immune reactions measured in vitro and those affecting the beta cells in vivo.